BioWorld

Nov. 5, 2002

With DN-101 In Phase II/III Trial, Novacea Closes $36M Series B

Novacea Inc. pulled in $36 million in its Series B round of financing, a sum the company says is validated by its drug in a later-stage trial and a solid group at the top. (BioWorld Today) Read More

Alexion Data Point To Potential For Treatment Over Long Term

Zinc-Finger Transcription Factor Switches On Body's Gene For Expression Of Multiple Proteins

FDA Tells Biogen To Clean Up Avonex Advertising Claims

Gilead Presents Combination Hepsera, Lamivudine Data

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld Science

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

Science in 2025: the best of the rest

BioWorld Science

A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.